Bora Pharmaceuticals (6472) Aktienübersicht
Bora Pharmaceuticals Co., LTD. erforscht und entwickelt, produziert, vertreibt und verkauft Arzneimittel weltweit. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 1/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 4/6 |
Belohnungen
Risikoanalyse
6472 Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Bora Pharmaceuticals Co., Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | NT$379.50 |
| 52-Wochen-Hoch | NT$795.00 |
| 52-Wochen-Tief | NT$330.50 |
| Beta | 0.57 |
| 1 Monat Veränderung | -9.43% |
| 3 Monate Veränderung | n/a |
| 1 Jahr Veränderung | -41.48% |
| 3 Jahre Veränderung | -22.39% |
| 5 Jahre Veränderung | 212.02% |
| Veränderung seit IPO | 912.45% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Narrativ-Update • Apr 12
6472: Renewed GSK Manufacturing Partnership Will Support Long Term Earnings Power
Analysts have adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around revenue growth of 29.12% and a profit margin of 20.96%. The implied fair value remains around NT$741.35 based on a forward P/E of 13.69.Narrativ-Update • Mar 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).Recent updates
Narrativ-Update • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Narrativ-Update • Apr 12
6472: Renewed GSK Manufacturing Partnership Will Support Long Term Earnings Power
Analysts have adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around revenue growth of 29.12% and a profit margin of 20.96%. The implied fair value remains around NT$741.35 based on a forward P/E of 13.69.Narrativ-Update • Mar 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).Narrativ-Update • Mar 13
6472: Renewed GSK Manufacturing Alliance Will Drive Long Term Upside Potential
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, pointing to stable views on fair value, discount rate, revenue growth assumptions, profit margins, and future P/E as the key reasons for maintaining their stance. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, extending their existing relationship and broadening GSK access to multiple Bora sites, including the oral solid dose facility in Maple Grove, Minnesota (Key Developments).Narrativ-Update • Feb 26
6472: Renewed GSK Partnership And Corealis Alliance Will Support Future Upside
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, citing largely stable assumptions on the discount rate, revenue growth, profit margin, and a slightly lower future P/E multiple. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, which gives GSK access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and a newer oral solid dose site in Maple Grove, Minnesota (Key Developments).Narrativ-Update • Feb 11
6472: Corealis Alliance Will Support Future Upside Through End To End Development
Analysts have modestly adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. This has resulted in a refreshed fair value estimate of about NT$741.02 per share.Narrativ-Update • Jan 28
6472: Corealis Alliance Will Drive Future Upside Through Integrated Development Path
Analysts have trimmed their price target for Bora Pharmaceuticals to reflect a fair value update to $741.02 from $788.87, citing slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E input in their models. What's in the News Bora Pharmaceuticals Co., Ltd.Narrativ-Update • Jan 11
6472: Corealis Alliance Will Support Future Upside Through Streamlined Development
Analysts have kept their price target for Bora Pharmaceuticals broadly unchanged at about $789, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that recent research has not materially shifted their valuation view. What's in the News Bora Pharmaceuticals Co., Ltd.Narrativ-Update • Dec 20
6472: Alliance With Corealis Will Support Stronger Long Term Performance
Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.Narrativ-Update • Dec 06
6472: Improved Profit Margins Will Support Stronger Long Term Performance
Narrative Update Analysts have nudged their price target on Bora Pharmaceuticals slightly higher to approximately $789 per share, reflecting modestly improved long term profit margin expectations, even though projected revenue growth has been tempered slightly. Valuation Changes Fair Value Estimate: unchanged at approximately NT$788.87 per share, indicating no material revision to the intrinsic value assessment.Narrativ-Update • Nov 21
6472: Improved Profit Margins Will Drive Stronger Performance Ahead
Analysts have lowered their price target for Bora Pharmaceuticals from $872.67 to $788.87. This adjustment is due to reduced revenue growth expectations, which are partially offset by projections of improved profit margins and a lower forward price-to-earnings ratio.Narrativ-Update • Sep 28
US CDMO Expansion And Specialty Focus Will Strengthen Position
The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.Neues Narrativ • Jul 20
US Facility Modernization Will Secure Future Specialty Success
Strategic shift to high-value CDMO services and facility upgrades has improved margins, driven growth, and positioned the company for market share gains.Analyseartikel • Mar 30
Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
With a median price-to-earnings (or "P/E") ratio of close to 20x in Taiwan, you could be forgiven for feeling...Analyseartikel • Jan 20
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) robust earnings report didn't manage to move the market for its stock...Analyseartikel • Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analyseartikel • Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) price-to-earnings (or "P/E") ratio of 34.2x might make it look like a...Analyseartikel • Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Key Insights The projected fair value for Bora Pharmaceuticals is NT$1,369 based on 2 Stage Free Cash Flow to Equity...Analyseartikel • Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) shareholders have had their patience rewarded with a 33% share price jump...Analyseartikel • Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Even though Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) posted strong earnings, investors appeared to be underwhelmed...Aktionärsrenditen
| 6472 | TW Pharmaceuticals | TW Markt | |
|---|---|---|---|
| 7D | 7.5% | 3.7% | 2.6% |
| 1Y | -41.5% | -5.2% | 94.7% |
Rendite im Vergleich zur Industrie: 6472 unter dem Niveau der Branche TW Pharmaceuticals , die im vergangenen Jahr eine Rendite von -5.2% erzielte.
Rendite vs. Markt: 6472 hinter dem Markt TW zurück, der im vergangenen Jahr eine Rendite von 94.7 erzielte.
Preisvolatilität
| 6472 volatility | |
|---|---|
| 6472 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in TW Market | 12.2% |
| 10% least volatile stocks in TW Market | 2.5% |
Stabiler Aktienkurs: 6472 hatte in den letzten 3 Monaten im Vergleich zum TW -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 6472Die wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Bobby Sheng | www.bora-corp.com |
Bora Pharmaceuticals Co., LTD. erforscht und entwickelt, produziert, vertreibt und verkauft Arzneimittel weltweit. Das Unternehmen ist in den Segmenten Vertrieb, Auftragsentwicklung und -herstellung sowie Sonstiges tätig.
Bora Pharmaceuticals Co., Ltd.'s Grundlagenzusammenfassung
| 6472 grundlegende Statistiken | |
|---|---|
| Marktanteil | NT$48.19b |
| Gewinn(TTM) | NT$1.68b |
| Umsatz(TTM) | NT$18.54b |
28.6x
Kurs-Gewinn-Verhältnis 2.6x
Kurs-Umsatz-VerhältnisIst 6472 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 6472 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | NT$18.54b |
| Kosten der Einnahmen | NT$11.13b |
| Bruttogewinn | NT$7.41b |
| Sonstige Ausgaben | NT$5.72b |
| Gewinn | NT$1.68b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 13.25 |
| Bruttomarge | 39.96% |
| Nettogewinnspanne | 9.08% |
| Schulden/Eigenkapital-Verhältnis | 100.9% |
Wie hat sich 6472 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
2.6%
Aktuelle Dividendenrendite74%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 08:55 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bora Pharmaceuticals Co., Ltd. wird von 7 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Chenghsin Lin | J.P. Morgan |
| null null | KGI Securities Co. Ltd. |